A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial have?
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial has 107 citations in the OpenAlex counts ScholarIQ stores.
When was A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial published?
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial has 2016 year in the ScholarIQ index.
What is the open-access status of A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial?
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial has bronze oa status in the ScholarIQ index.
What is the DOI of A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial?
The DOI for A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial is on the source record.
What is the PMID of A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial?
The PMID for A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial is on the source record.
What is the OpenAlex record for A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial?
The OpenAlex for A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial is on the source record.